Psychiatric pharmacists enhance substance use disorder (SUD) care by managing medications and treatment strategies.

There are evolving recommendations for aspirin use, including optimal drug dosages and patient selection for effective cardiovascular prevention.

Tradipitant, a novel NK-1 receptor antagonist, was proven effective at reducing the incidence and severity of nausea and vomiting in individuals with motion sickness.

FDA considers relaxing dietary supplement warning labels, raising concerns about consumer safety and informed decision-making among users.

Researchers develop a novel therapy combining molecular glues and KRAS inhibitors, showing promise in treating KRAS-mutant non–small cell lung cancer.

GLP-1 receptor agonists show potential in reducing alcohol cravings and addiction behaviors, offering hope for treating substance use disorders.